Quantexa Appoints Industry Luminaries to its Advisory Board to Accelerate Growth Plans
September 22, 2023 01:00 ET
|
Quantexa
LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Quantexa, the global leader in Decision Intelligence (DI) solutions for the private and public sectors, announced today that it has appointed three...
Aptose to Present at the Cantor Global Healthcare Conference
September 18, 2023 07:45 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023 16:30 ET
|
Marker Therapeutics
Executed comprehensive non-dilutive agreement with Cell ReadyTM, resulting in an extended financial runway into the fourth quarter of 2025 Appointed Juan Vera, M.D. as President and Chief Executive...
Vor Bio Reports Second Quarter 2023 Financial Results and Provides Company Update
August 10, 2023 16:05 ET
|
Vor Biopharma
Next trem-cel clinical data update expected by year-end 2023VCAR33ALLO IND cleared by U.S. FDA; Rapidly activating sites toward study initiationSecured non-exclusive license to Cas9 gene-edited HSCs ...
Aptose Reports Results for the Second Quarter 2023
August 10, 2023 16:02 ET
|
Aptose Biosciences, Inc.
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67%...
Vor Bio to Participate in the Wedbush PacGrow Healthcare Conference
August 01, 2023 08:00 ET
|
Vor Biopharma
CAMBRIDGE, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, will host in-person 1x1 investor meetings at the 2023 Wedbush PacGrow...
Quantexa Bringing Total Global Investment in Artificial Intelligence Research and Development to Over $250M by 2027
July 09, 2023 19:01 ET
|
Quantexa
Quantexa CEO outlines vision for investment in support of UK Government’s plan to make UK an AI Hub, which includes: Over $155M in new global investments aimed at accelerating enterprise...
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
June 26, 2023 07:00 ET
|
Marker Therapeutics
HOUSTON, June 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) (Marker or the Company), a clinical-stage immuno-oncology company focusing on developing next-generation T...
Aptose Presents Highlights from Clinical Update
June 10, 2023 12:00 ET
|
Aptose Biosciences, Inc.
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat...